{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:33:44Z","timestamp":1787168024734,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.reprotox.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T11:56:26Z","timestamp":1551786986000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-7934","authenticated-orcid":false,"given":"Yusuf Cem","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-9559","authenticated-orcid":false,"given":"Jonathan Luke","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Keskin-Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"Erol-Coskun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.reprotox.2019.03.001_bib0005","first-page":"e171","article-title":"Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis","volume":"20","author":"Einarson","year":"2013","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.reprotox.2019.03.001_bib0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/1753495X15621154","article-title":"Ondansetron and pregnancy: understanding the data","volume":"9","author":"Kennedy","year":"2016","journal-title":"Obstet. Med."},{"issue":"3","key":"10.1016\/j.reprotox.2019.03.001_bib0015","first-page":"e555","article-title":"Surviving morning sickness successfully: from patient\u2019s perception to rational management","volume":"21","author":"Maltepe","year":"2014","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"issue":"2 Suppl","key":"10.1016\/j.reprotox.2019.03.001_bib0020","first-page":"S31","article-title":"The pharmacologic management of nausea and vomiting of pregnancy","volume":"63","author":"Niebyl","year":"2014","journal-title":"J. Fam. Pract."},{"issue":"1","key":"10.1016\/j.reprotox.2019.03.001_bib0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/jp.2010.54","article-title":"Health-related quality of life in women with nausea and vomiting of pregnancy: the importance of psychosocial context","volume":"31","author":"Munch","year":"2011","journal-title":"J. Perinatol."},{"issue":"September 3","key":"10.1016\/j.reprotox.2019.03.001_bib0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/01674820009075620","article-title":"Psychosocial morbidity among women with nausea and vomiting of pregnancy: prevalence and association with anti-emetic therapy","volume":"21","author":"Mazzotta","year":"2000","journal-title":"J. Psychosom. Obstet. Gynaecol."},{"issue":"June 6","key":"10.1016\/j.reprotox.2019.03.001_bib0035","first-page":"430","article-title":"Ondansetron--the first of a new class of antiemetic agents","volume":"10","author":"Chaffee","year":"1991","journal-title":"Clin. Pharm."},{"issue":"2","key":"10.1016\/j.reprotox.2019.03.001_bib0040","first-page":"e184","article-title":"The management of nausea and vomiting of pregnancy and hyperemesis gravidarum--a 2013 update","volume":"20","author":"Maltepe","year":"2013","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.reprotox.2019.03.001_bib0045","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1471-0528.2004.00236.x","article-title":"The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study","volume":"111","author":"Einarson","year":"2004","journal-title":"BJOG"},{"key":"10.1016\/j.reprotox.2019.03.001_bib0050","doi-asserted-by":"crossref","first-page":"909860","DOI":"10.1155\/2013\/909860","article-title":"Off-label use of ondansetron in pregnancy in Western Australia","volume":"2013","author":"Colvin","year":"2013","journal-title":"Biomed Res. Int."},{"issue":"February 9","key":"10.1016\/j.reprotox.2019.03.001_bib0055","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1056\/NEJMoa1211035","article-title":"Ondansetron in pregnancy and risk of adverse fetal outcomes","volume":"368","author":"Pasternak","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"October","key":"10.1016\/j.reprotox.2019.03.001_bib0060","article-title":"Ondansetron use in early pregnancy and the risk of congenital malformations - a register-based nationwide cohort study. Abstract 25 ISPE 2013","author":"Andersen","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.reprotox.2019.03.001_bib0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.reprotox.2014.10.017","article-title":"Use of ondansetron during pregnancy and congenital malformations","volume":"50","author":"Danielsson","year":"2014","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2019.03.001_bib0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.reprotox.2016.04.027","article-title":"Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States","volume":"62","author":"Fejzo","year":"2016","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2019.03.001_bib0075","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00228-005-0055-1","article-title":"Use of antiemetic drugs during pregnancy in Sweden","volume":"61","author":"Asker","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.reprotox.2019.03.001_bib0080","series-title":"National Birth Defects Prevention Study. Medications Used to Treat Nausea and Vomiting of Pregnancy and the Risk of Selected Birth Defects","author":"Anderka","year":"2019"},{"key":"10.1016\/j.reprotox.2019.03.001_bib0085","first-page":"401","article-title":"Ondansetron for the treatment of nausea and vomiting of pregnancy and the risk of birth defects","volume":"24","author":"Van Bennekom","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"5","key":"10.1016\/j.reprotox.2019.03.001_bib0090","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/pds.4185","article-title":"Antiemetic use among pregnant women in the United States: the escalating use of ondansetron","volume":"26","author":"Taylor","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.reprotox.2019.03.001_bib0095","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Altman DG for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.reprotox.2019.03.001_bib0100","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.reprotox.2019.03.001_bib0105","series-title":"The Newcastle-ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses","author":"Wells","year":"2019"},{"key":"10.1016\/j.reprotox.2019.03.001_bib0110","series-title":"EUROCAT Subgroups of Congenital Anomalies","author":"European Surveillance of Congenital Anomalies","year":"2019"},{"key":"10.1016\/j.reprotox.2019.03.001_bib0115","series-title":"Minor Anomalies for Exclusion","author":"European Surveillance of Congenital Anomalies","year":"2019"},{"key":"10.1016\/j.reprotox.2019.03.001_bib0120","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0","author":"The Cochrane Collaboration","year":"2011"},{"issue":"7414","key":"10.1016\/j.reprotox.2019.03.001_bib0125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7568","key":"10.1016\/j.reprotox.2019.03.001_bib0130","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","article-title":"The case of the misleading funnel plot","volume":"333","author":"Lau","year":"2006","journal-title":"BMJ"},{"issue":"August","key":"10.1016\/j.reprotox.2019.03.001_bib0135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.reprotox.2017.06.048","article-title":"Erratum to \"Use of ondansetron during pregnancy and congenital malformations in the infant\" [Reprod. Toxicol. 50C (2017) 134-137]","volume":"71","author":"Danielsson","year":"2017","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.reprotox.2019.03.001_bib0140","unstructured":"File:Human-critical periods of development.jpg - Embryology [Internet]. Embryology.med.unsw.edu.au. [cited 20 December 2018]. Available from: https:\/\/embryology.med.unsw.edu.au\/embryology\/index.php\/File:Human-critical_periods_of_development.jpg."},{"key":"10.1016\/j.reprotox.2019.03.001_bib0145","unstructured":"Appendix 2 Germ Layer Derivatives - Review of Medical Embryology Book - LifeMap Discovery [Internet]. Discovery.lifemapsc.com. [cited 20 December 2018]. Available from: https:\/\/discovery.lifemapsc.com\/library\/review-of-medical-embryology\/appendix-2-germ-layer-derivatives."},{"issue":"December 4","key":"10.1016\/j.reprotox.2019.03.001_bib0150","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/bdrc.21083","article-title":"Cleft palate: a clinical review","volume":"102","author":"Shkoukani","year":"2014","journal-title":"Birth Defects Res. C Embryo Today"},{"issue":"September 3","key":"10.1016\/j.reprotox.2019.03.001_bib0155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1741-4520.2008.00189.x","article-title":"Specified critical period of different congenital abnormalities: a new approach for human teratological studies","volume":"48","author":"Czeizel","year":"2008","journal-title":"Congenit Anom (Kyoto)"},{"issue":"3","key":"10.1016\/j.reprotox.2019.03.001_bib0160","first-page":"165","article-title":"Prenatal diagnosis of congenital renal and urinary tract malformations","volume":"3","author":"Hindryckx","year":"2011","journal-title":"Facts Views Vis. Obgyn"},{"issue":"October 3","key":"10.1016\/j.reprotox.2019.03.001_bib0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.diff.2012.06.003","article-title":"Molecular mechanisms of external genitalia development","volume":"84","author":"Blaschko","year":"2012","journal-title":"Differentiation"},{"issue":"June 10","key":"10.1016\/j.reprotox.2019.03.001_bib0170","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1100\/tsw.2010.112","article-title":"Penile embryology and anatomy","volume":"29","author":"Yiee","year":"2010","journal-title":"Sci. World J."},{"issue":"October","key":"10.1016\/j.reprotox.2019.03.001_bib0175","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.reprotox.2018.08.018","article-title":"Ondansetron and teratogenicity in rats: Evidence for a mechanism mediated via embryonic hERG blockade","volume":"81","author":"Danielsson","year":"2018","journal-title":"Reprod. Toxicol."},{"issue":"August 2","key":"10.1016\/j.reprotox.2019.03.001_bib0180","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/AOG.0000000000002679","article-title":"National birth defects prevention study. Ondansetron for treatment of nausea and vomiting of pregnancy and the risk of specific birth defects","volume":"132","author":"Parker","year":"2018","journal-title":"Obstet. Gynecol."},{"issue":"May 5","key":"10.1016\/j.reprotox.2019.03.001_bib0185","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/AOG.0000000000001388","article-title":"Ondansetron use in pregnancy and birth defects: a systematic review","volume":"127","author":"Carstairs","year":"2016","journal-title":"Obstet. Gynecol."},{"issue":"July 7","key":"10.1016\/j.reprotox.2019.03.001_bib0190","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jogc.2017.10.024","article-title":"Ondansetron in pregnancy and the risk of congenital malformations: a systematic review","volume":"40","author":"Lavecchia","year":"2018","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"10.1016\/j.reprotox.2019.03.001_bib0195","article-title":"The safety of ondansetron and chlorpromazine for hyperemesis gravidarum in first trimester pregnancy","volume":"20.2","author":"\u00d6zdemirci","year":"2014","journal-title":"Gynecol. Obst. Reprod. Med."},{"issue":"March 3","key":"10.1016\/j.reprotox.2019.03.001_bib0200","article-title":"Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes","volume":"210","author":"Larrimer","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"June","key":"10.1016\/j.reprotox.2019.03.001_bib0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejogrb.2015.03.028","article-title":"Neurodevelopmental delay in children exposed in utero to hyperemesis gravidarum","volume":"189","author":"Fejzo","year":"2015","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.reprotox.2019.03.001_bib0210","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CLEP.S9304","article-title":"Medical databases in studies of drug teratogenicity: methodological issues","volume":"2","author":"Ehrenstein","year":"2010","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.reprotox.2019.03.001_bib0215","article-title":"Vitamin K Deficiency Embryopathy from Hyperemesis Gravidarum","volume":"2015","author":"Lane","year":"2015","journal-title":"Case Rep. Obstet. Gynecol."},{"key":"10.1016\/j.reprotox.2019.03.001_bib0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.reprotox.2018.10.010","article-title":"First trimester ondansetron exposure and risk of structural birth defects","volume":"83","author":"Zambelli-Weiner","year":"2018","journal-title":"Reprod. Toxicol."},{"issue":"23","key":"10.1016\/j.reprotox.2019.03.001_bib0225","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1001\/jama.2018.18307","article-title":"Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring","volume":"320","author":"Huybrechts","year":"2018","journal-title":"JAMA"}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089062381830529X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089062381830529X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:48:48Z","timestamp":1760190528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089062381830529X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":45,"alternative-id":["S089062381830529X"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2019.03.001","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}